Compare GHM & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GHM | DMRA |
|---|---|---|
| Founded | 1936 | 2011 |
| Country | United States | United States |
| Employees | 732 | 7 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 1994 | 2020 |
| Metric | GHM | DMRA |
|---|---|---|
| Price | $109.77 | $22.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $73.33 | $43.00 |
| AVG Volume (30 Days) | 271.8K | ★ 392.9K |
| Earning Date | 06-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.90 | N/A |
| EPS | ★ 1.12 | N/A |
| Revenue | ★ $245,293,000.00 | N/A |
| Revenue This Year | $14.54 | N/A |
| Revenue Next Year | $18.23 | N/A |
| P/E Ratio | $96.35 | ★ N/A |
| Revenue Growth | ★ 16.86 | N/A |
| 52 Week Low | $46.08 | $16.50 |
| 52 Week High | $119.04 | $28.76 |
| Indicator | GHM | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 58.03 | 54.48 |
| Support Level | $88.46 | $22.71 |
| Resistance Level | N/A | $27.70 |
| Average True Range (ATR) | 7.43 | 2.09 |
| MACD | 0.57 | 0.29 |
| Stochastic Oscillator | 72.23 | 68.47 |
Graham Corp designs and manufactures mission-critical fluid, power, heat transfer, vacuum, and mixing technologies for the Defense, Energy & Process, and Space industries. In Defense, its equipment is used in nuclear and non-nuclear propulsion, power, fluid transfer, thermal management, and mixing systems. In Energy & Process industries, it supplies equipment for vacuum, heat transfer, mixing, and fluid transfer applications used in oil refining, chemical facilities, fertilizers, ethylene, methanol, energetics, food & beverage, medical, and alternative energy applications such as hydrogen and geothermal processes. In the Space industry, its equipment is used in propulsion, power, thermal management, mixing, and life support systems. It operates in the United States and other countries.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.